Frontlight ResearchEarly access
CompletedPhase 4
GO TEST FINALE
Key facts
- Who runs it
- Sint Maartenskliniek
- Where
- Netherlands1 site in 1 countryChoose a country to see its sites
- Trial code
- EU 2024-511111-13-01
- NL9245
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 310 people enrolled
- Started
- 9 Jul 2024
- Ended
- 16 Jun 2025
- Type of study
- Interventional
- Record updated
- 9 July 2024
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Patients with clinical diagnosis of gout and/or fulfilling the 2015 ACR-EULAR gout criteria
- Use of ULT (allopurinol, benzbromarone and/or febuxostat); Achieved remission for ≥ 12 months based on adapted preliminary gout remission criteria (29). o Free of flares and/or clinically apparent tophi during the last 12 months o Serum urate ≤0.36 mmol/l at baseline and all values in the last 12 months should not be >0.36 mmol/l o Pain due to gout <2 using a 10-point Likert-type scale at baseline o Patient global assessment of gout disease activity <2 using a 10-point Likert-type scale at baseline; Age ≥18 years and mentally competent; Signed written informed consent
Who cannot take part
- Not being able to speak, read or write Dutch well enough; No ability to measure the outcome of the study in the participant (e.g. life expectancy <2 years, planned relocation out of reach of study center); A strong contra-indication for glucocorticoids, NSAIDs AND colchicine, as this hampers flare treatment; Use of ULT (also) for any other indication than gout (for example nephrolithiasis); Currently taking regular glucocorticoids, and/or colchicine, and/or interleukine-1 inhibitors for any diagnosis and/or the use of regular NSAID intake for gout activity; A history of myocardial infarction or stroke in the past six months and/or congestive heart failure NYHA class III or IV
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
1) To assess the between strategy difference in proportion of participants fulfilling adapted preliminary gout remission criteria (no tophi, no flares, NRS pain due to gout <2 and disease activity <2, but independent of sUA level), during the last six months of the 24 month follow-up period. 2) To assess the incremental cost-effectiveness in euro per QALY gained for T2T compared to T2S.
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- GOut TrEatment STrategy (GO TEST) FINALE study, a multicentre pragmatic randomized superiority trial of continuation versus cessation of urate lowering therapies in gout in remission.
- Record updated
- 9 July 2024